AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04922801 — intervention group
Intervention type: DEVICE
Intervention: Patient-led radiation monitor (SELFIE)
Description: Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results.~After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope.~On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire.
Study NCT05694169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renal Autologous Cell Therapy (REACT)
Description: Autologous selected renal cells (SRC)
Study NCT05475535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Cognitive Behavioural Therapy
Study NCT04922801 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LAB TEST
Description: Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.
Study NCT05475535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion
Description: Self-Compassion focused exercises
Study NCT05475535 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Engagement in a mobile application (Cooperation skills)
Study NCT06621511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OurSleepKit
Description: OurSleepKit is developed as an app including a patient version and a partner version, to be downloaded on the patient's or partner's mobile devices at home. The goal of OurSleepKit is to coach mutual engagement and model positive partner involvement in CPAP treatment, thus motivating greater CPAP adherence. Using OurSleepKit, both the patient and partner will complete periodic assessments tracking various aspects of their sleep and CPAP use. The assessment data are then processed by OurSleepKit to provide customized and dynamically updated support content consisting of brief story-telling videos featuring real-life couples' experiences emphasizing positive dyadic coping and problem-solving strategies. OurSleepKit delivers timely tailored prompts through push notifications on the users' mobile devices' screens, linked to relevant support content, to facilitate positive conversation in the dyad and offer in-the-moment support for CPAP use.
Study NCT06700486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SOCKET SHIELD
Description: in implant dentistry
Study NCT06700486 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Immediate implant and sticky bone
Description: in implant dentistry
Study NCT06702228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Six minute walk test (6MWT)
Description: Assessment of exercise capacity by the carrying out of a 6MWT at 0, 6 and 12 months.
Study NCT06702228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computer-tomography of the thorax (CT Thorax)
Description: Radiological assessment via CT Thorax, preferably high-resolution CT thorax at baseline on entering the study and at one year. CT images will be collected on study end. CT images in all subjects will be evaluated by three readers blinded to any other interpretation and conforming to ATS-guidelines. Coded data from CT scans will be shared with our collaborator Professor Simon Walsh at Imperial College, London who will use computational methods to identify novel radiologic phenotypes linked to disease behaviour of our patient's fibrotic lung disease.
Study NCT04707924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Treatment of scars with fractional Er:YAG 2940nm laser.
Study NCT04921930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Oral Product
Description: Dose escalation intake of artesunate
Study NCT04257682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine is a long-lasting dense sensory-motor block that can last up to four hours. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 6.75 mg to 8.25 mg for the knee, and 7.5 mg to 9 mg for the hip.
Study NCT04257682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine is a long-acting local anesthetic that is known for its differential sensory-motor block. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 9 mg to 11 mg for the knee, and 10 mg to 12 mg for the hip.
Study NCT04257682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine
Description: Mepivacaine is an intermediate-acting local anesthetic producing shorting and motor-sparing blocks. It will be administered once, as part of the spinal anesthetic. The dosage varies based on age and joint, from 40 mg to 50 mg for the knee, and 45 mg to 55 mg for the hip.
Study NCT04750122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning
Description: The choice of chemotherapy is based on the PTC drug sensitivity results.
Study NCT06382987 — intervention group
Intervention type: DRUG
Intervention: Deucravacitinib
Description: According to the product label
Study NCT06382987 — intervention group
Intervention type: DRUG
Intervention: Apremilast
Description: According to the product label
Study NCT06368063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
Study NCT06368063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy drugs
Description: Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)~· Gemcitabine combine with capecitabine~Gemcitabine 1000mg/m\^2 intravenous infusion for more than 30 minutes, day 1, 8, 15,repeat every 4 weeks for a total of 6 cycles.~· mFOLFIRINOX solution~Oxaliplatin 85mg/m\^2 intravenous infusion for 2 hours, day 1 Ilitacan 150mg/m\^2 intravenous infusion for more than 30-90 minutes, day 1 Leucovorin calcium 400mg/m\^2 intravenous infusion for 2 hours, day 1 5-FU 2400mg/m\^2, continuous intravenous infusion for 46 hours, repeated every 2 weeks, administered until 24 weeks.~* Gemcitabine monotherapy~  1000mg/m\^2 intravenous infusion, day 1 qw x 7, rest for 1 week Afterwards, qw × 3, take a week off, and administer medication for 6 months.~* Tegio capsules monotherapy~Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months.
Study NCT05729620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access
Description: After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
Study NCT05195320 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinvention with MS
Description: A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
Study NCT05195320 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reinvention with MS
Description: A manualized group therapy to build self-efficacy among people living with multiple sclerosis.
Study NCT06702228 — intervention group
Intervention type: OTHER
Intervention: Quality of life questionnaires.
Description: Qality of life questionnaires including; modified Medical Research Council (mMRC) dyspnea scale, The King's Brief Interstitial Lung Disease Questionnaire (KBILD), The Leister Cough Questionnaire and the EQ-5D-3L questionnaire are measured at 0, 6 and 12 months
Study NCT06702228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: 10ml of serum will be collected for DNA extraction and analysed for causative and at risk genetic mutations
Study NCT06702228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: We will carry out spirometry at baseline, 6 and 2 months including forced vital capacity and diffusing capacity of the lungs for carbon monoxide.
Study NCT05074550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPMX-T003
Description: As an observation and evaluation method, for each dose, in principle, inpatient observation is performed for 1 week from the day before administration, and then safety and pharmacodynamic tests are evaluated by visiting the hospital every 2 weeks.
Study NCT06702228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serology
Description: Serology which may indicate an underlying diagnosis of ILD will be carried out on study entry. This will include a full blood count, renal profile, liver profile, C-reactive protein, creatine kinase, erythrocyte sedimentation rate, antinuclear antibodies, anticyclic citrullinated peptide antibodies, rheumatoid factor, an extended myositis antibody panel, sjögren's antibodies, scleroderma antibodies and a hypersensivity pneumonitis panel if clinically indicated.
Study NCT06702228 — intervention group
Intervention type: OTHER
Intervention: Other Quality of Life Questionnaires
Description: Patient Global Assessment and Clinician Global Assessment scores completed at 0, 6 and 12 months
Study NCT06702228 — intervention group
Intervention type: OTHER
Intervention: PatientMPower Home Monitoring App
Description: Continuous at home monitoring of patients using home-based digital spirometry and pulse-oximetry with real-time feedback readings to patient and clinician. Smartphone app for patients, spirometer and pulse oximeter are connected to the app via Bluetooth. Patients are asked to take 2 readings per week.
Study NCT06702488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: 20 mg/kg as a loading dose over 10 minutes before induction then a maintenance dose of 5 mg/kg/hour, which will also be discontinued at the skin closure.
Study NCT05366725 — intervention group
Intervention type: DRUG
Intervention: Avelumab
Description: As provided in real world practice
Study NCT05850260 — intervention group
Intervention type: DEVICE
Intervention: Macintosh laryngoscope
Description: During the pre-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations in the operation room according to the standard of care using the standard Macintosh direct laryngoscope as a first intubation option
Study NCT05850260 — intervention group
Intervention type: DEVICE
Intervention: Videolaryngoscope
Description: During the post-implementation period (6 months), the 35 assigned attending anesthetists will perform all tracheal intubations using their personal McGrath Mac videolaryngoscope as a first intubation option.
Study NCT06303687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-PAT
Description: Virtual Reality Pain Alleviation Therapy (VR-PAT) played on a Pico Neo 3 Pro Eye device
Study NCT06411782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foam roller
Description: In foam roller application, a partitioned FR from the Trigger Point Grid 2.0 brand, measuring 33x14 cm and weighing 0.9 kg, with an inner part made of polyvinylchloride (PVC), will be used. Participants will roll the segmented FR with slight flexion-extension by placing the FR on the SCM muscle to apply FR from the starting point to the end point of that muscle region for the selected SCM muscle, with the person in the side stance position against the wall. This action will consist of 3 sets of 1 minute each, with a 30-second rest period between each set. It will be applied once for each region, including the right and left SCM muscle.
Study NCT06411782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: Inspiratory muscle training will be done with a resistive exercise device at 80% of MIP max and for 30 breaths.
Study NCT05338671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic
Description: Patients will receive inferior alveolar nerve block injection following endodontic treatment.
Study NCT05523531 — intervention group
Intervention type: OTHER
Intervention: Self-administered questionnaires
Description: * Neuropathic Eye Pain Questionnaire~* 5-item Dry Eye Evaluation Questionnaire (DEQ-5)~* Visual Impact Assessment Questionnaire~* Concise Ophthalmic Pain Questionnaire~* Questionnaire to evaluate the effectiveness and tolerance of treatments~* Chronic pain questionnaire
Study NCT05523531 — intervention group
Intervention type: PROCEDURE
Intervention: Bilateral ophthalmologic examination
Description: * Examination of the ocular surface and eyelids Slit lamp with fluorescein instillation: Oxford scheme and Break-up time, Schirmer's test, Oxybuprocaine test~* Lipiview® test~* Examination of corneal sensitivity with the Cochet-Bonnet esthesiometer~* In vivo morphological examination of the subepithelial nerve plexus of the cornea by confocal microscopy
Study NCT06634407 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transcatheter closure
Description: using transcatheter closure of PDA to detect outcome of patients with PDA
Study NCT04692103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 16 Alpha-Fluoroestradiol
Description: Undergo F-18 FES PET/CT
Study NCT04692103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo F-18 FES PET/CT
Study NCT04692103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo F-18 FES PET/CT
Study NCT04692103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG PET/CT
Study NCT04692103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG PET/CT
Study NCT04692103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG PET/CT
Study NCT04692103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT05571618 — intervention group
Intervention type: DRUG
Intervention: ADC
Description: Patients with prior exposure to ADC (either in the adjuvant setting or metastatic disease are allowed).
Study NCT04748510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Functionally Aligned Total Knee Arthroplasty
Description: Femoral + tibial osteotomy planned for equal resection of femoral condyles to replicate patient anatomy. In coronal plane, distal femoral resection of 6.5mm subchondral bone from medial + lateral condyles, adjusted 1-3mm for compensation of wear. Proximal tibia, 7mm resection from subchondral bone from medial + lateral tibial plateau. Sagittal plane, resection angle determined intraoperatively to closely match native femoral flexion + tibial slope. Axial plane: posterior femoral resection 6.5mm from the subchondral bone of medial and lateral posterior condyles. Tibial rotation aligned to Akagi's line. Adjustments will be made to bony alignment to balance soft tissues within boundaries of 6° varus/3° valgus HKA alignment. Femoral component alignment limited to 6° valgus/3° varus in coronal plane. Tibial alignment limited 6° varus/3° valgus in coronal plane. Combined flexion of components limited to 10° flexion. Soft tissue release if balance within boundaries not achieved.
Study NCT04748510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanically Aligned Total Knee Arthroplasty
Description: Tibial and femoral osteotomies in the coronal plane will be planned perpendicular to the tibial and femoral mechanical axes respectively to achieve neutral overall alignment. Soft tissue balance will be assessed and minor adjustments to bony alignment made to balance the knees with a maximal adjustment of two degrees valgus and two degrees varus of coronal alignment from neutral. Femoral rotation will be planned to surgical epicondylar axis and adjustments to rotation made to allow equal flexion and extension balance (to within 1mm). If balance can not be achieved within these boundaries then soft tissue release will be undertaken. In the sagittal plane, 0-3° degrees of posterior tibial slope and 0-5° of femoral component flexion will be used to optimise implant sizing whilst preventing notching. In the axial plane, the tibial component aligned to Akagi's line, which connects the medial border of the patellar tendon attachment to the middle of the posterior cruciate ligament.
Study NCT05508061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Cartridge [Lyumjev]
Description: Administration of Lyumjev in combination with the AP system
Study NCT05508061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro Cartridge
Description: Administration of Humalog in combination with the AP system (standard therapy)
Study NCT05196412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PulseOn Arrhythmia Monitor device
Description: Wearing of the wrist device for a period of two weeks
Study NCT05459636 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-resistance inspiratory muscle strength training
Description: Participants will perform high-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
Study NCT05459636 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Very-low-resistance inspiratory muscle strength training
Description: Participants will perform very-low-resistance inspiratory muscle strength training on a daily basis for eight weeks using a handheld device that produces resistance that increases the effort of breathing in.
Study NCT06572410 — intervention group
Intervention type: DEVICE
Intervention: EnVisio Navigation System
Description: Patient will be undergoing BCS Breast Conserving Surgery treatment for DCIS or invasive breast cancer with EnVisio Navigation System.
Study NCT06414499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTNK-tPA
Description: 0.25mg/kg, the maximum dose does not exceed 25mg: 1 vial is dissolved in 3ml of sterile water for injection to prepare a medicinal solution with a concentration of 5.33mg/ml. Calculate the total amount of the drug according to the weight of participant, and the maximum dose shall not exceed 25 mg. It is administered as a single bolus intravenous injection, and the injection is completed within 5-10 seconds.
Study NCT06414499 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Standard medical care according to the guideline (Stroke. 2019;50(12): e344-e418.). Antiplatelet therapy is chosen by researchers-Single/dual antiplatelet therapy can be chosen.
Study NCT04844229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral transnasal sphenopalatine ganglion block.
Description: SPG block will be performed with the patient in supine position using cotton-tipped plastic hollow applicator inserted in the nose with the swab soaked in 1.5 ml 10%lignocaine. The applicator will be inserted parallel to the floor of the nose until resistance encountered. The swab will be rested in the pterygopalatine fossa superior to the middle turbinate and removed after 10 min. This procedure will be repeated in the other nostril too.
Study NCT04844229 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided greater occipital nerve block.
Description: GONB will be performed with the patients lying in prone position using high frequency (6-13 MHz) probe of Siemens Acuson X300 machine placed in transverse orientation lateral to external occipital protuberance parallel to the superior nuchal line to detect occipital artery where the nerve is located medial to it 1.5inch; then 20 gauge needle will be inserted out of plane to avoid vascular injury. 4 ml of treatment solution containing 2.5 mg/ml bupivacaine and 1 mg/ml dexamethasone (prepared by adding 2 ml bupivacaine 0.5% + 1 ml dexamethasone + 1 ml saline) will be injected on each side.
Study NCT05800288 — intervention group
Intervention type: DRUG
Intervention: Propofol
Description: Patients will be observationally included in the Elveld TCI or Schnider TCI group. The TCI model is choosen at anesthesiologist's discreption, as suggested in literature
Study NCT04631055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug coated balloon
Description: paclitaxel coated balloon catheter for intracranial PTA treatment
Study NCT04631055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stent system
Description: The Intracranial Stent System comprises of a balloon expandable stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.The product, APOLLO™ stent system, has the indication of endovascular treatment for intracranial stenosis approved by NMPA.
Study NCT04959175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.
Study NCT04959175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Stem cell transplant
Study NCT04959175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV infusion over 30-60 minutes once daily for 5 days (Pre-Transplant days -6 through -2).
Study NCT04959175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg), then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +60 with no taper. May be continued beyond the protocol specified stop date if there is GVHD or mixed chimerism.